Article

Immunogenicity and safety of an Omicron XBB.1.16 adapted vaccine for COVID-19: Interim results from a randomized, controlled, non-inferiority clinical trial

2024-04-19

Abstract excerpt

<h4>Background</h4> Global COVID-19 vaccination adapts to protect populations from emerging variants. This communication presents interim findings from the new Omicron XBB adapted PHH-1V81 vaccine compared to a XBB adapted mRNA vaccine against XBB and JN.1 SARS-CoV-2 strains. <h4>Methods</h4> In a Phase IIb/III pivotal trial, adults previously vaccinated with a primary scheme and at least one booster dose of an EU...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 16a1be9b-459a-59af-9684-6285324f076f
DOI: 10.1101/2024.04.19.24306064

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Immunogenicity and safety of an Omicron XBB.1.16 adapted vaccine for COVID-19: Interim results from a randomized, controlled, non-inferiority clinical trialDOI 10.1101/2024.04.19.24306064Read

Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concernSemantic proximity Read

Humoral Immune Response Against XBB.1.5 and BQ.1.1 SARS-COV-2 Variants of a Fourth Dose of PHH-1V Vaccine in Adult Subject: Preliminary Results of HIPRA-HH-2 Extension StudySemantic proximity Read

Effectiveness of XBB.1.5 Vaccines Against Omicron SubvariantsSemantic proximity Read

Preclinical Characterization of the Omicron XBB.1.5-Adapted BNT162b2 COVID-19 VaccineSemantic proximity Read

Safety and Immunogenicity of XBB.1.5-Containing mRNA VaccinesSemantic proximity Read

Antibody Response of Heterologous vs Homologous mRNA Vaccine Boosters Against the SARS-CoV-2 Omicron Variant: Interim Results from the PRIBIVAC Study, A Randomized Clinical TrialSemantic proximity Read

COVID-19 Vaccine Effectiveness and the Evidence on Boosters: A Systematic Review (with Partial Evidence on the Omicron Variant)Semantic proximity Read

Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine (mRNA-1273.815) in preventing COVID-19-related hospitalizations and medical encounters among adults in the United States: An interim analysisSemantic proximity Read

Immunogenicity and safety of DS-5670d, an mRNA-based COVID-19 vaccine targeting omicron XBB.1.5: Results from a phase 3, randomized, active-controlled study in adults and children aged ≥12 yearsSemantic proximity Read

Neutralizing potency of COVID-19 vaccines against the SARS-CoV-2 Omicron (B.1.1.529) variantSemantic proximity Read

Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron VariantSemantic proximity Read

Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity — IVY Network, 26 Hospitals, October 18, 2023–March 9, 2024Semantic proximity Read